# Nucleix

Source: https://onco.cc/companies/nucleix/  
OnCo record `nucleix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nucleix makes urine and blood tests that read chemical marks on DNA to spot bladder cancer coming back and, in development, to find lung cancer early.

## Summary

Nucleix, based in Rehovot, Israel with a US office in San Diego, develops methylation-based liquid biopsy tests on its EpiCheck platform, which uses PCR and next-generation sequencing to detect disease-specific DNA methylation changes. Bladder EpiCheck is a urine test analysing 15 methylation markers for surveillance of non-muscle invasive bladder cancer recurrence alongside cystoscopy; it is CE-marked for primary and recurrent bladder and upper tract urothelial cancer and received FDA 510(k) clearance in May 2023, the first methylation-based urine qPCR test cleared for this use. A. Menarini Diagnostics distributes it in Europe under a 2024 partnership, with pivotal data published in 2024 and 2025. Lung EpiCheck, a blood test for early detection of lung cancer in high-risk individuals, is in development. In April 2021 the company raised $55 million led by RA Capital Management to advance it.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Rehovot
- Type: diagnostics
- Website: https://nucleix.com/

## Notes

- The 2021 release does not name the round; recorded as Series C on the basis that it followed earlier rounds, treat the label as uncertain. Founding year not sourced.

## Sources

- Official website: https://nucleix.com/
- FDA 510(k) clearance for Bladder EpiCheck (May 2023): https://nucleix.com/wp-content/uploads/2023/05/PR_Nucleix_Bladder-EpiCheck-FDA-Clearance.pdf
- $55 million financing (April 2021): https://nucleix.com/blog/news_and_events/nucleix-secures-55-million-funding-led-by-ra-capital-management-and-additional-prominent-life-science-investors-to-advance-lung-epicheck-for-early-detection-of-lung-cancer/

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Bladder EpiCheck urine methylation test](https://onco.cc/technologies/bladder-epicheck/), [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Urine tests for bladder cancer (cytology, FISH, RNA and methylation)](https://onco.cc/technologies/urine-bladder-cancer-tests/)
- companies: [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/nucleix.json